#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0181] A labeled base is incorporated into the complementary sequence by the use of a polymerase, e.g., a polymerase with a 3' to 5' exonuclease activity (e.g., DNA polymerase I, the Klenow fragment, DNA polymerase III, T4 DNA polymerase, and T7 DNA polymerase).
1-1	0-1	[	_	_	
1-2	1-5	0181	_	_	
1-3	5-6	]	_	_	
1-4	7-8	A	_	_	
1-5	9-16	labeled	_	_	
1-6	17-21	base	_	_	
1-7	22-24	is	_	_	
1-8	25-37	incorporated	_	_	
1-9	38-42	into	_	_	
1-10	43-46	the	_	_	
1-11	47-60	complementary	_	_	
1-12	61-69	sequence	_	_	
1-13	70-72	by	_	_	
1-14	73-76	the	_	_	
1-15	77-80	use	_	_	
1-16	81-83	of	_	_	
1-17	84-85	a	_	_	
1-18	86-96	polymerase	_	_	
1-19	96-97	,	_	_	
1-20	98-101	e.g	_	_	
1-21	101-102	.	_	_	
1-22	102-103	,	_	_	
1-23	104-105	a	_	_	
1-24	106-116	polymerase	_	_	
1-25	117-121	with	_	_	
1-26	122-123	a	_	_	
1-27	124-125	3	_	_	
1-28	125-126	'	_	_	
1-29	127-129	to	_	_	
1-30	130-131	5	_	_	
1-31	131-132	'	_	_	
1-32	133-144	exonuclease	_	_	
1-33	145-153	activity	_	_	
1-34	154-155	(	_	_	
1-35	155-158	e.g	_	_	
1-36	158-159	.	_	_	
1-37	159-160	,	_	_	
1-38	161-164	DNA	_	_	
1-39	165-175	polymerase	_	_	
1-40	176-177	I	_	_	
1-41	177-178	,	_	_	
1-42	179-182	the	_	_	
1-43	183-189	Klenow	_	_	
1-44	190-198	fragment	_	_	
1-45	198-199	,	_	_	
1-46	200-203	DNA	_	_	
1-47	204-214	polymerase	_	_	
1-48	215-218	III	_	_	
1-49	218-219	,	_	_	
1-50	220-222	T4	_	_	
1-51	223-226	DNA	_	_	
1-52	227-237	polymerase	_	_	
1-53	237-238	,	_	_	
1-54	239-242	and	_	_	
1-55	243-245	T7	_	_	
1-56	246-249	DNA	_	_	
1-57	250-260	polymerase	_	_	
1-58	260-261	)	_	_	
1-59	261-262	.	_	_	

#Text=Following detection of the incorporated labeled base, the polymerase replaces the terminally labeled base with a corresponding unlabelled base, thus permitting further sequencing to occur.
#Text=[0182] In yet another embodiment, the nucleotide sequence of the oligonucleotide tag is determined by the use of single molecule sequencing by synthesis methods described in, for example, PCT Publication No.
2-1	263-272	Following	_	_	
2-2	273-282	detection	_	_	
2-3	283-285	of	_	_	
2-4	286-289	the	_	_	
2-5	290-302	incorporated	_	_	
2-6	303-310	labeled	_	_	
2-7	311-315	base	_	_	
2-8	315-316	,	_	_	
2-9	317-320	the	_	_	
2-10	321-331	polymerase	_	_	
2-11	332-340	replaces	_	_	
2-12	341-344	the	_	_	
2-13	345-355	terminally	_	_	
2-14	356-363	labeled	_	_	
2-15	364-368	base	_	_	
2-16	369-373	with	_	_	
2-17	374-375	a	_	_	
2-18	376-389	corresponding	_	_	
2-19	390-400	unlabelled	_	_	
2-20	401-405	base	_	_	
2-21	405-406	,	_	_	
2-22	407-411	thus	_	_	
2-23	412-422	permitting	_	_	
2-24	423-430	further	_	_	
2-25	431-441	sequencing	_	_	
2-26	442-444	to	_	_	
2-27	445-450	occur	_	_	
2-28	450-451	.	_	_	
2-29	452-453	[	_	_	
2-30	453-457	0182	_	_	
2-31	457-458	]	_	_	
2-32	459-461	In	_	_	
2-33	462-465	yet	_	_	
2-34	466-473	another	_	_	
2-35	474-484	embodiment	_	_	
2-36	484-485	,	_	_	
2-37	486-489	the	_	_	
2-38	490-500	nucleotide	_	_	
2-39	501-509	sequence	_	_	
2-40	510-512	of	_	_	
2-41	513-516	the	_	_	
2-42	517-532	oligonucleotide	_	_	
2-43	533-536	tag	_	_	
2-44	537-539	is	_	_	
2-45	540-550	determined	_	_	
2-46	551-553	by	_	_	
2-47	554-557	the	_	_	
2-48	558-561	use	_	_	
2-49	562-564	of	_	_	
2-50	565-571	single	_	_	
2-51	572-580	molecule	_	_	
2-52	581-591	sequencing	_	_	
2-53	592-594	by	_	_	
2-54	595-604	synthesis	_	_	
2-55	605-612	methods	_	_	
2-56	613-622	described	_	_	
2-57	623-625	in	_	_	
2-58	625-626	,	_	_	
2-59	627-630	for	_	_	
2-60	631-638	example	_	_	
2-61	638-639	,	_	_	
2-62	640-643	PCT	_	_	
2-63	644-655	Publication	_	_	
2-64	656-658	No	_	_	
2-65	658-659	.	_	_	

#Text=WO 2005/080605, the entire contents of which are expressly incorporated by reference.
3-1	660-662	WO	_	_	
3-2	663-667	2005	_	_	
3-3	667-668	/	_	_	
3-4	668-674	080605	_	_	
3-5	674-675	,	_	_	
3-6	676-679	the	_	_	
3-7	680-686	entire	_	_	
3-8	687-695	contents	_	_	
3-9	696-698	of	_	_	
3-10	699-704	which	_	_	
3-11	705-708	are	_	_	
3-12	709-718	expressly	_	_	
3-13	719-731	incorporated	_	_	
3-14	732-734	by	_	_	
3-15	735-744	reference	_	_	
3-16	744-745	.	_	_	

#Text=The benefit of using this technology is that it eliminates the need for DNA amplification prior to sequencing, thus, abolishing the introduction of amplification errors and bias.
4-1	746-749	The	_	_	
4-2	750-757	benefit	_	_	
4-3	758-760	of	_	_	
4-4	761-766	using	_	_	
4-5	767-771	this	_	_	
4-6	772-782	technology	_	_	
4-7	783-785	is	_	_	
4-8	786-790	that	_	_	
4-9	791-793	it	_	_	
4-10	794-804	eliminates	_	_	
4-11	805-808	the	_	_	
4-12	809-813	need	_	_	
4-13	814-817	for	_	_	
4-14	818-821	DNA	_	_	
4-15	822-835	amplification	_	_	
4-16	836-841	prior	_	_	
4-17	842-844	to	_	_	
4-18	845-855	sequencing	_	_	
4-19	855-856	,	_	_	
4-20	857-861	thus	_	_	
4-21	861-862	,	_	_	
4-22	863-873	abolishing	_	_	
4-23	874-877	the	_	_	
4-24	878-890	introduction	_	_	
4-25	891-893	of	_	_	
4-26	894-907	amplification	_	_	
4-27	908-914	errors	_	_	
4-28	915-918	and	_	_	
4-29	919-923	bias	_	_	
4-30	923-924	.	_	_	

#Text=Briefly, the encoding oligonucleotide is hybridized to a universal primer immobilized on a solid surface.
5-1	925-932	Briefly	_	_	
5-2	932-933	,	_	_	
5-3	934-937	the	_	_	
5-4	938-946	encoding	_	_	
5-5	947-962	oligonucleotide	_	_	
5-6	963-965	is	_	_	
5-7	966-976	hybridized	_	_	
5-8	977-979	to	_	_	
5-9	980-981	a	_	_	
5-10	982-991	universal	_	_	
5-11	992-998	primer	_	_	
5-12	999-1010	immobilized	_	_	
5-13	1011-1013	on	_	_	
5-14	1014-1015	a	_	_	
5-15	1016-1021	solid	_	_	
5-16	1022-1029	surface	_	_	
5-17	1029-1030	.	_	_	

#Text=The oligonucleotide:primer duplexes are visualized by, e.g., illuminating the surface with a laser and imaging with a digital TV camera connected to a microscope, and the positions of all the duplexes on the surface are recorded.
6-1	1031-1034	The	_	_	
6-2	1035-1050	oligonucleotide	_	_	
6-3	1050-1051	:	_	_	
6-4	1051-1057	primer	_	_	
6-5	1058-1066	duplexes	_	_	
6-6	1067-1070	are	_	_	
6-7	1071-1081	visualized	_	_	
6-8	1082-1084	by	_	_	
6-9	1084-1085	,	_	_	
6-10	1086-1089	e.g	_	_	
6-11	1089-1090	.	_	_	
6-12	1090-1091	,	_	_	
6-13	1092-1104	illuminating	_	_	
6-14	1105-1108	the	_	_	
6-15	1109-1116	surface	_	_	
6-16	1117-1121	with	_	_	
6-17	1122-1123	a	_	_	
6-18	1124-1129	laser	_	_	
6-19	1130-1133	and	_	_	
6-20	1134-1141	imaging	_	_	
6-21	1142-1146	with	_	_	
6-22	1147-1148	a	_	_	
6-23	1149-1156	digital	_	_	
6-24	1157-1159	TV	_	_	
6-25	1160-1166	camera	_	_	
6-26	1167-1176	connected	_	_	
6-27	1177-1179	to	_	_	
6-28	1180-1181	a	_	_	
6-29	1182-1192	microscope	_	_	
6-30	1192-1193	,	_	_	
6-31	1194-1197	and	_	_	
6-32	1198-1201	the	_	_	
6-33	1202-1211	positions	_	_	
6-34	1212-1214	of	_	_	
6-35	1215-1218	all	_	_	
6-36	1219-1222	the	_	_	
6-37	1223-1231	duplexes	_	_	
6-38	1232-1234	on	_	_	
6-39	1235-1238	the	_	_	
6-40	1239-1246	surface	_	_	
6-41	1247-1250	are	_	_	
6-42	1251-1259	recorded	_	_	
6-43	1259-1260	.	_	_	

#Text=DNA polymerase and one type of fluorescently labeled nucleotide, e.g., A, is added to the surface and incorporated into the appropriate primer.
7-1	1261-1264	DNA	_	_	
7-2	1265-1275	polymerase	_	_	
7-3	1276-1279	and	_	_	
7-4	1280-1283	one	_	_	
7-5	1284-1288	type	_	_	
7-6	1289-1291	of	_	_	
7-7	1292-1305	fluorescently	_	_	
7-8	1306-1313	labeled	_	_	
7-9	1314-1324	nucleotide	_	_	
7-10	1324-1325	,	_	_	
7-11	1326-1329	e.g	_	_	
7-12	1329-1330	.	_	_	
7-13	1330-1331	,	_	_	
7-14	1332-1333	A	_	_	
7-15	1333-1334	,	_	_	
7-16	1335-1337	is	_	_	
7-17	1338-1343	added	_	_	
7-18	1344-1346	to	_	_	
7-19	1347-1350	the	_	_	
7-20	1351-1358	surface	_	_	
7-21	1359-1362	and	_	_	
7-22	1363-1375	incorporated	_	_	
7-23	1376-1380	into	_	_	
7-24	1381-1384	the	_	_	
7-25	1385-1396	appropriate	_	_	
7-26	1397-1403	primer	_	_	
7-27	1403-1404	.	_	_	

#Text=Subsequently, the polymerase and the unincorporated nucleotides are washed from the surface and the incorporated nucleotide is visualized by, e.g., illuminating the surface with a laser and imaging with a camera as before to record the positions of the incorporated nucleotides.
8-1	1405-1417	Subsequently	_	_	
8-2	1417-1418	,	_	_	
8-3	1419-1422	the	_	_	
8-4	1423-1433	polymerase	_	_	
8-5	1434-1437	and	_	_	
8-6	1438-1441	the	_	_	
8-7	1442-1456	unincorporated	_	_	
8-8	1457-1468	nucleotides	_	_	
8-9	1469-1472	are	_	_	
8-10	1473-1479	washed	_	_	
8-11	1480-1484	from	_	_	
8-12	1485-1488	the	_	_	
8-13	1489-1496	surface	_	_	
8-14	1497-1500	and	_	_	
8-15	1501-1504	the	_	_	
8-16	1505-1517	incorporated	_	_	
8-17	1518-1528	nucleotide	_	_	
8-18	1529-1531	is	_	_	
8-19	1532-1542	visualized	_	_	
8-20	1543-1545	by	_	_	
8-21	1545-1546	,	_	_	
8-22	1547-1550	e.g	_	_	
8-23	1550-1551	.	_	_	
8-24	1551-1552	,	_	_	
8-25	1553-1565	illuminating	_	_	
8-26	1566-1569	the	_	_	
8-27	1570-1577	surface	_	_	
8-28	1578-1582	with	_	_	
8-29	1583-1584	a	_	_	
8-30	1585-1590	laser	_	_	
8-31	1591-1594	and	_	_	
8-32	1595-1602	imaging	_	_	
8-33	1603-1607	with	_	_	
8-34	1608-1609	a	_	_	
8-35	1610-1616	camera	_	_	
8-36	1617-1619	as	_	_	
8-37	1620-1626	before	_	_	
8-38	1627-1629	to	_	_	
8-39	1630-1636	record	_	_	
8-40	1637-1640	the	_	_	
8-41	1641-1650	positions	_	_	
8-42	1651-1653	of	_	_	
8-43	1654-1657	the	_	_	
8-44	1658-1670	incorporated	_	_	
8-45	1671-1682	nucleotides	_	_	
8-46	1682-1683	.	_	_	

#Text=The fluorescent label is removed from each incorporated nucleotide and the process is repeated with the next nucleotide, e.g., G, stepping through A, C, G, T, until the desired read-length is achieved.
#Text=[0183] One group of fluorescent dyes suitable for this method of sequencing is fluorescence resonance energy transfer (FRET) dyes, including donor and acceptor energy fluorescent dyes and linkers such as, for example, Cy3 and Cy5.
9-1	1684-1687	The	_	_	
9-2	1688-1699	fluorescent	_	_	
9-3	1700-1705	label	_	_	
9-4	1706-1708	is	_	_	
9-5	1709-1716	removed	_	_	
9-6	1717-1721	from	_	_	
9-7	1722-1726	each	_	_	
9-8	1727-1739	incorporated	_	_	
9-9	1740-1750	nucleotide	_	_	
9-10	1751-1754	and	_	_	
9-11	1755-1758	the	_	_	
9-12	1759-1766	process	_	_	
9-13	1767-1769	is	_	_	
9-14	1770-1778	repeated	_	_	
9-15	1779-1783	with	_	_	
9-16	1784-1787	the	_	_	
9-17	1788-1792	next	_	_	
9-18	1793-1803	nucleotide	_	_	
9-19	1803-1804	,	_	_	
9-20	1805-1808	e.g	_	_	
9-21	1808-1809	.	_	_	
9-22	1809-1810	,	_	_	
9-23	1811-1812	G	_	_	
9-24	1812-1813	,	_	_	
9-25	1814-1822	stepping	_	_	
9-26	1823-1830	through	_	_	
9-27	1831-1832	A	_	_	
9-28	1832-1833	,	_	_	
9-29	1834-1835	C	_	_	
9-30	1835-1836	,	_	_	
9-31	1837-1838	G	_	_	
9-32	1838-1839	,	_	_	
9-33	1840-1841	T	_	_	
9-34	1841-1842	,	_	_	
9-35	1843-1848	until	_	_	
9-36	1849-1852	the	_	_	
9-37	1853-1860	desired	_	_	
9-38	1861-1872	read-length	_	_	
9-39	1873-1875	is	_	_	
9-40	1876-1884	achieved	_	_	
9-41	1884-1885	.	_	_	
9-42	1886-1887	[	_	_	
9-43	1887-1891	0183	_	_	
9-44	1891-1892	]	_	_	
9-45	1893-1896	One	_	_	
9-46	1897-1902	group	_	_	
9-47	1903-1905	of	_	_	
9-48	1906-1917	fluorescent	_	_	
9-49	1918-1922	dyes	_	_	
9-50	1923-1931	suitable	_	_	
9-51	1932-1935	for	_	_	
9-52	1936-1940	this	_	_	
9-53	1941-1947	method	_	_	
9-54	1948-1950	of	_	_	
9-55	1951-1961	sequencing	_	_	
9-56	1962-1964	is	_	_	
9-57	1965-1977	fluorescence	_	_	
9-58	1978-1987	resonance	_	_	
9-59	1988-1994	energy	_	_	
9-60	1995-2003	transfer	_	_	
9-61	2004-2005	(	_	_	
9-62	2005-2009	FRET	_	_	
9-63	2009-2010	)	_	_	
9-64	2011-2015	dyes	_	_	
9-65	2015-2016	,	_	_	
9-66	2017-2026	including	_	_	
9-67	2027-2032	donor	_	_	
9-68	2033-2036	and	_	_	
9-69	2037-2045	acceptor	_	_	
9-70	2046-2052	energy	_	_	
9-71	2053-2064	fluorescent	_	_	
9-72	2065-2069	dyes	_	_	
9-73	2070-2073	and	_	_	
9-74	2074-2081	linkers	_	_	
9-75	2082-2086	such	_	_	
9-76	2087-2089	as	_	_	
9-77	2089-2090	,	_	_	
9-78	2091-2094	for	_	_	
9-79	2095-2102	example	_	_	
9-80	2102-2103	,	_	_	
9-81	2104-2107	Cy3	_	_	
9-82	2108-2111	and	_	_	
9-83	2112-2115	Cy5	_	_	
9-84	2115-2116	.	_	_	

#Text=FRET is a phenomenon described in, for example, Selvin (1995) Methods in Enzym. 246:300.
10-1	2117-2121	FRET	_	_	
10-2	2122-2124	is	_	_	
10-3	2125-2126	a	_	_	
10-4	2127-2137	phenomenon	_	_	
10-5	2138-2147	described	_	_	
10-6	2148-2150	in	_	_	
10-7	2150-2151	,	_	_	
10-8	2152-2155	for	_	_	
10-9	2156-2163	example	_	_	
10-10	2163-2164	,	_	_	
10-11	2165-2171	Selvin	_	_	
10-12	2172-2173	(	_	_	
10-13	2173-2177	1995	_	_	
10-14	2177-2178	)	_	_	
10-15	2179-2186	Methods	_	_	
10-16	2187-2189	in	_	_	
10-17	2190-2195	Enzym	_	_	
10-18	2195-2196	.	_	_	
10-19	2197-2200	246	_	_	
10-20	2200-2201	:	_	_	
10-21	2201-2204	300	_	_	
10-22	2204-2205	.	_	_	

#Text=FRET can detect the incorporation of multiple nucleotides into a single oligonucleotide molecule and is, thus, useful for sequencing the encoding oligonucleotides of the invention.
11-1	2206-2210	FRET	_	_	
11-2	2211-2214	can	_	_	
11-3	2215-2221	detect	_	_	
11-4	2222-2225	the	_	_	
11-5	2226-2239	incorporation	_	_	
11-6	2240-2242	of	_	_	
11-7	2243-2251	multiple	_	_	
11-8	2252-2263	nucleotides	_	_	
11-9	2264-2268	into	_	_	
11-10	2269-2270	a	_	_	
11-11	2271-2277	single	_	_	
11-12	2278-2293	oligonucleotide	_	_	
11-13	2294-2302	molecule	_	_	
11-14	2303-2306	and	_	_	
11-15	2307-2309	is	_	_	
11-16	2309-2310	,	_	_	
11-17	2311-2315	thus	_	_	
11-18	2315-2316	,	_	_	
11-19	2317-2323	useful	_	_	
11-20	2324-2327	for	_	_	
11-21	2328-2338	sequencing	_	_	
11-22	2339-2342	the	_	_	
11-23	2343-2351	encoding	_	_	
11-24	2352-2368	oligonucleotides	_	_	
11-25	2369-2371	of	_	_	
11-26	2372-2375	the	_	_	
11-27	2376-2385	invention	_	_	
11-28	2385-2386	.	_	_	

#Text=Sequencing methods using FRET are described in, for example, PCT Publication No.
12-1	2387-2397	Sequencing	_	_	
12-2	2398-2405	methods	_	_	
12-3	2406-2411	using	_	_	
12-4	2412-2416	FRET	_	_	
12-5	2417-2420	are	_	_	
12-6	2421-2430	described	_	_	
12-7	2431-2433	in	_	_	
12-8	2433-2434	,	_	_	
12-9	2435-2438	for	_	_	
12-10	2439-2446	example	_	_	
12-11	2446-2447	,	_	_	
12-12	2448-2451	PCT	_	_	
12-13	2452-2463	Publication	_	_	
12-14	2464-2466	No	_	_	
12-15	2466-2467	.	_	_	

#Text=WO 2005/080605, the entire contents of which are expressly incorporated by reference.
13-1	2468-2470	WO	_	_	
13-2	2471-2475	2005	_	_	
13-3	2475-2476	/	_	_	
13-4	2476-2482	080605	_	_	
13-5	2482-2483	,	_	_	
13-6	2484-2487	the	_	_	
13-7	2488-2494	entire	_	_	
13-8	2495-2503	contents	_	_	
13-9	2504-2506	of	_	_	
13-10	2507-2512	which	_	_	
13-11	2513-2516	are	_	_	
13-12	2517-2526	expressly	_	_	
13-13	2527-2539	incorporated	_	_	
13-14	2540-2542	by	_	_	
13-15	2543-2552	reference	_	_	
13-16	2552-2553	.	_	_	

#Text=Alternatively, quantum dots can be used as a labeling moiety on the different types of nucleotides for use in sequencing reactions.
#Text=[0184] Once single ligands are identified by the above-described process, various levels of analysis can be applied to yield structure-activity relationship information and to guide further optimization of the affinity, specificity and bioactivity of the ligand.
14-1	2554-2567	Alternatively	_	_	
14-2	2567-2568	,	_	_	
14-3	2569-2576	quantum	_	_	
14-4	2577-2581	dots	_	_	
14-5	2582-2585	can	_	_	
14-6	2586-2588	be	_	_	
14-7	2589-2593	used	_	_	
14-8	2594-2596	as	_	_	
14-9	2597-2598	a	_	_	
14-10	2599-2607	labeling	_	_	
14-11	2608-2614	moiety	_	_	
14-12	2615-2617	on	_	_	
14-13	2618-2621	the	_	_	
14-14	2622-2631	different	_	_	
14-15	2632-2637	types	_	_	
14-16	2638-2640	of	_	_	
14-17	2641-2652	nucleotides	_	_	
14-18	2653-2656	for	_	_	
14-19	2657-2660	use	_	_	
14-20	2661-2663	in	_	_	
14-21	2664-2674	sequencing	_	_	
14-22	2675-2684	reactions	_	_	
14-23	2684-2685	.	_	_	
14-24	2686-2687	[	_	_	
14-25	2687-2691	0184	_	_	
14-26	2691-2692	]	_	_	
14-27	2693-2697	Once	_	_	
14-28	2698-2704	single	_	_	
14-29	2705-2712	ligands	_	_	
14-30	2713-2716	are	_	_	
14-31	2717-2727	identified	_	_	
14-32	2728-2730	by	_	_	
14-33	2731-2734	the	_	_	
14-34	2735-2750	above-described	_	_	
14-35	2751-2758	process	_	_	
14-36	2758-2759	,	_	_	
14-37	2760-2767	various	_	_	
14-38	2768-2774	levels	_	_	
14-39	2775-2777	of	_	_	
14-40	2778-2786	analysis	_	_	
14-41	2787-2790	can	_	_	
14-42	2791-2793	be	_	_	
14-43	2794-2801	applied	_	_	
14-44	2802-2804	to	_	_	
14-45	2805-2810	yield	_	_	
14-46	2811-2829	structure-activity	_	_	
14-47	2830-2842	relationship	_	_	
14-48	2843-2854	information	_	_	
14-49	2855-2858	and	_	_	
14-50	2859-2861	to	_	_	
14-51	2862-2867	guide	_	_	
14-52	2868-2875	further	_	_	
14-53	2876-2888	optimization	_	_	
14-54	2889-2891	of	_	_	
14-55	2892-2895	the	_	_	
14-56	2896-2904	affinity	_	_	
14-57	2904-2905	,	_	_	
14-58	2906-2917	specificity	_	_	
14-59	2918-2921	and	_	_	
14-60	2922-2933	bioactivity	_	_	
14-61	2934-2936	of	_	_	
14-62	2937-2940	the	_	_	
14-63	2941-2947	ligand	_	_	
14-64	2947-2948	.	_	_	

#Text=For ligands derived from the same scaffold, three-dimensional molecular modeling can be employed to identify significant structural features common to the ligands, thereby generating families of small-molecule ligands that presumably bind at a common site on the target biomolecule.
#Text=[0185] A variety of screening approaches can be used to obtain ligands that possess high affinity for one target but significantly weaker affinity for another closely related target.
15-1	2949-2952	For	_	_	
15-2	2953-2960	ligands	_	_	
15-3	2961-2968	derived	_	_	
15-4	2969-2973	from	_	_	
15-5	2974-2977	the	_	_	
15-6	2978-2982	same	_	_	
15-7	2983-2991	scaffold	_	_	
15-8	2991-2992	,	_	_	
15-9	2993-3010	three-dimensional	_	_	
15-10	3011-3020	molecular	_	_	
15-11	3021-3029	modeling	_	_	
15-12	3030-3033	can	_	_	
15-13	3034-3036	be	_	_	
15-14	3037-3045	employed	_	_	
15-15	3046-3048	to	_	_	
15-16	3049-3057	identify	_	_	
15-17	3058-3069	significant	_	_	
15-18	3070-3080	structural	_	_	
15-19	3081-3089	features	_	_	
15-20	3090-3096	common	_	_	
15-21	3097-3099	to	_	_	
15-22	3100-3103	the	_	_	
15-23	3104-3111	ligands	_	_	
15-24	3111-3112	,	_	_	
15-25	3113-3120	thereby	_	_	
15-26	3121-3131	generating	_	_	
15-27	3132-3140	families	_	_	
15-28	3141-3143	of	_	_	
15-29	3144-3158	small-molecule	_	_	
15-30	3159-3166	ligands	_	_	
15-31	3167-3171	that	_	_	
15-32	3172-3182	presumably	_	_	
15-33	3183-3187	bind	_	_	
15-34	3188-3190	at	_	_	
15-35	3191-3192	a	_	_	
15-36	3193-3199	common	_	_	
15-37	3200-3204	site	_	_	
15-38	3205-3207	on	_	_	
15-39	3208-3211	the	_	_	
15-40	3212-3218	target	_	_	
15-41	3219-3230	biomolecule	_	_	
15-42	3230-3231	.	_	_	
15-43	3232-3233	[	_	_	
15-44	3233-3237	0185	_	_	
15-45	3237-3238	]	_	_	
15-46	3239-3240	A	_	_	
15-47	3241-3248	variety	_	_	
15-48	3249-3251	of	_	_	
15-49	3252-3261	screening	_	_	
15-50	3262-3272	approaches	_	_	
15-51	3273-3276	can	_	_	
15-52	3277-3279	be	_	_	
15-53	3280-3284	used	_	_	
15-54	3285-3287	to	_	_	
15-55	3288-3294	obtain	_	_	
15-56	3295-3302	ligands	_	_	
15-57	3303-3307	that	_	_	
15-58	3308-3315	possess	_	_	
15-59	3316-3320	high	_	_	
15-60	3321-3329	affinity	_	_	
15-61	3330-3333	for	_	_	
15-62	3334-3337	one	_	_	
15-63	3338-3344	target	_	_	
15-64	3345-3348	but	_	_	
15-65	3349-3362	significantly	_	_	
15-66	3363-3369	weaker	_	_	
15-67	3370-3378	affinity	_	_	
15-68	3379-3382	for	_	_	
15-69	3383-3390	another	_	_	
15-70	3391-3398	closely	_	_	
15-71	3399-3406	related	_	_	
15-72	3407-3413	target	_	_	
15-73	3413-3414	.	_	_	

#Text=One screening strategy is to identify ligands for both biomolecules in parallel experiments and to subsequently eliminate common ligands by a cross-referencing comparison.
16-1	3415-3418	One	*[1]	17-2[2_1]	
16-2	3419-3428	screening	*[1]	_	
16-3	3429-3437	strategy	*[1]	_	
16-4	3438-3440	is	*[1]	_	
16-5	3441-3443	to	*[1]	_	
16-6	3444-3452	identify	*[1]	_	
16-7	3453-3460	ligands	*[1]	_	
16-8	3461-3464	for	*[1]	_	
16-9	3465-3469	both	*[1]	_	
16-10	3470-3482	biomolecules	*[1]	_	
16-11	3483-3485	in	*[1]	_	
16-12	3486-3494	parallel	*[1]	_	
16-13	3495-3506	experiments	*[1]	_	
16-14	3507-3510	and	*[1]	_	
16-15	3511-3513	to	*[1]	_	
16-16	3514-3526	subsequently	*[1]	_	
16-17	3527-3536	eliminate	*[1]	_	
16-18	3537-3543	common	*[1]	_	
16-19	3544-3551	ligands	*[1]	_	
16-20	3552-3554	by	*[1]	_	
16-21	3555-3556	a	*[1]	_	
16-22	3557-3574	cross-referencing	*[1]	_	
16-23	3575-3585	comparison	*[1]	_	
16-24	3585-3586	.	*[1]	_	

#Text=In this method, ligands for each biomolecule can be separately identified as disclosed above.
17-1	3587-3589	In	_	_	
17-2	3590-3594	this	*[2]	_	
17-3	3595-3601	method	*[2]	_	
17-4	3601-3602	,	_	_	
17-5	3603-3610	ligands	_	_	
17-6	3611-3614	for	_	_	
17-7	3615-3619	each	_	_	
17-8	3620-3631	biomolecule	_	_	
17-9	3632-3635	can	_	_	
17-10	3636-3638	be	_	_	
17-11	3639-3649	separately	_	_	
17-12	3650-3660	identified	_	_	
17-13	3661-3663	as	_	_	
17-14	3664-3673	disclosed	_	_	
17-15	3674-3679	above	_	_	
17-16	3679-3680	.	_	_	

#Text=This method is compatible with both immobilized target biomolecules and target biomolecules free in solution.
18-1	3681-3685	This	_	_	
18-2	3686-3692	method	_	_	
18-3	3693-3695	is	_	_	
18-4	3696-3706	compatible	_	_	
18-5	3707-3711	with	_	_	
18-6	3712-3716	both	_	_	
18-7	3717-3728	immobilized	_	_	
18-8	3729-3735	target	_	_	
18-9	3736-3748	biomolecules	_	_	
18-10	3749-3752	and	_	_	
18-11	3753-3759	target	_	_	
18-12	3760-3772	biomolecules	_	_	
18-13	3773-3777	free	_	_	
18-14	3778-3780	in	_	_	
18-15	3781-3789	solution	_	_	
18-16	3789-3790	.	_	_	
